Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Head and Neck Cancer (HNC) Therapeutics Market Snapshot (2023 to 2033)

The global Head and Neck Cancer (HNC) Therapeutics market is expected to surpass an impressive valuation of US$ 5.19 Billion in 2033 and is projected to exhibit a compound annual growth rate (CAGR) of 12.6% from 2023 to 2033.

Advances in the detection and treatment of head and neck cancer (HNC) are expected to drive market growth since they are less expensive and more precise to approach than surgeries. The increased incidences of multiple kinds of HNCs, as well as the rising geriatric population, are significant market drivers.

Head and neck cancers are categorized based on where they occur. These include the oral cavity, pharynx, larynx, paranasal sinuses, nasal cavity, and salivary glands. Increased alcohol and cigarette consumption is a major cause of head and neck cancer. Alcohol and cigarette use are thought to be responsible for 75% of head and neck cancers. Cancer will be the leading cause of death, accounting for over 10 million deaths, or one out of every six. As a consequence, this aspect is expected to propel market expansion.

Moreover, the United Nations estimates that there were approximately 727 million individuals aged 60 and over in the world by 2020. Aging deteriorates the immune system and makes individuals more susceptible to various types of HNCs, creating a market for therapeutic drugs for therapeutic strategies.

Report Attribute Details
Expected Market Value (2023) US$ 1.58 Billion
Anticipated Forecast Value (2033) US$ 5.19 Billion
Projected Growth Rate (2023 to 2033) 12.6% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Head and Neck Cancer (HNC) Therapeutics Demand Analysis vs. Forecast 2023 to 2033

Patients with head and neck cancer are at significant risk of SARS-CoV-2 infection because they need prevalent outpatient services to evaluate disease processes and use systemic drug therapies to regulate deadly disease conditions. During the COVID-19 pandemic, the popularity of nonsurgical therapeutics such as chemotherapy, immunosuppression, and targeted therapy accelerated. Therefore, during the historical period the head and neck cancer (HNC) therapeutics market grew rapidly with a CAGR of 11.8%.

Furthermore, an increment in Research and Development activities involving the creation of novel therapeutic targets and multidisciplinary treatment approaches is anticipated to boost the survival rate of individuals with head and neck cancers. For instance, Merck/Debiopharm's Xevinapant is presently in phase III clinical trials for therapies for squamous head and neck cancer. The FDA has designated it as a revolutionary therapy.

Which are Some Prominent Drivers of the Head and Neck Cancer (HNC) Therapeutics Market?

Presence of a comprehensive pipeline and the expected launch of these products benefit sales growth

The existence of a robust product pipeline and their anticipated launch will aid sales growth. Tipifarnib (Farnesyltransferase Inhibitor), tiragolumab (anti-TIGIT), Tecentriq (atezolizumab), Rozlytrek (entrectinib), and Afatinib are among the products in development. Over the forecast timeframe, market growth is expected to be stimulated by the satisfactory implementation of trials and subsequent approval. Tipifarnib, advanced by Kura Oncology, Inc., was designated as a revolutionary therapy by the US Food and Drug Administration in February 2021 for the treatment of individuals with head and neck squamous cell carcinoma (HNSCC). This is a powerful, specific, and orally administered medicine.

Rise in Prevalence of Cancer Patients to Push the Market Growth

As the number of individuals suffering from head and neck cancers continues to rise dramatically, there is an enormous spike in the demand for inventive cancer treatments all over the world. There has been a significant increase in the number of cases of head and neck cancer in recent years.

Based on a World Health Organization (WHO) report, more than 550,000 cases of head and neck cancer are observed each year, with approximately 300,000 deaths occurring as a result of these cancers. People are selecting treatments such as chemotherapy and radiotherapy to alleviate symptoms and boost their likelihood of surviving. Soaring cancer treatment adoption will continue to stimulate the expansion of the head and neck cancer (HNC) therapeutics market during the projected timeframe.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Projected to be Faced by the Market?

Chemotherapy-Related Side Effects to Limit Market Growth

Head and neck cancer is commonly treated with a combination of radiation and chemotherapy. Hair loss, speech difficulties, and diminished natural voice are among the side effects.

Furthermore, people who have had cancer surgery have trouble swallowing. Hair loss is a common side effect of chemotherapy, but it does not influence everybody. Individuals can inquire with their doctor if it is most likely a drug therapy side effect.

Region-Wise Insights

What Makes North America the Largest Market for Head and Neck Cancer (HNC) Therapeutics?

The high prevalence of head and neck cancer cases is predicted to expand North American Market

North America dominated the market, accounting for approximately 45% of total revenue in 2021. Government assistance for the advancement of the medical industry, favorable reimbursement policies, increased disease consciousness, increased Research and Development activities and effortless access to high-quality healthcare facilities are among the major factors influencing regional market expansion.

Based on the Cancer Research Institute, roughly 54,000 people were diagnosed with various types of HNC in 2021, with nearly 11,000 deaths reported throughout the United States. In the United States, head and neck cancer records about 4% of all cancers as per the report published by Cancer.net in 2022. As a result, the market in North America is expected to grow rapidly owing to the high prevalence of head and neck cancer cases.

Why is Asia Pacific Considered a Lucrative Region for the Head and Neck Cancer (HNC) Therapeutics Market?

Growing utilization of immunotherapeutic drugs drives the market growth

The market for head and neck cancer therapeutics is predicted to expand the fastest in the Asia Pacific over the projected timeframe. The burgeoning geriatric population, in addition to the increasing use of immunotherapeutic drugs such as Pembrolizumab (Keytruda) and Nivolumab (Opdivo) for the treatment of various types of HNC, are expected to stimulate market growth in the future.

China is a major source of head and neck cancer, accounting for approximately 10% of all systemic malignant cancers each year. The survival rate of head and neck tumors is increasing as medical standards improve. After standardized treatment, the 5-year overall survival rate for head and neck tumors is around 80% in China. As a result, this factor is expected to contribute to the growth of the regional market.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-Wise Insights

Which Therapy Type will dominate the Market?

Novel immunotherapy drug approvals drive segment growth

The immunotherapy segment dominated the industry and accounted for 44% of total revenue in 2022. Based on the Cancer Research Institute, there are presently two approved PD-L1 inhibitors for the diagnosis of patients suffering from head and neck cancer: Nivolumab (Opdivo) and Pembrolizumab (Keytruda).

Dostarlimab (Jemperli) is being evaluated in Phase II clinical trials for the treatment of metastatic or reoccurring head and neck squamous cell carcinoma. As a result, the authorization of innovative immunotherapy drugs is anticipated to propel the growth of this segment.

Which Channel Segment is Expected to Garner the Highest Market Share?

Retail and specialty pharmacies accounted for the majority of profits

In 2022, the retail and specialty pharmacies segment ruled the market, accounting for 58% of total revenue. The supremacy can be credited to producers' choice for marketing their products owing to easy access to medications and minimal distribution expenses.

Humana specialty pharmacy, Accredo, CVS Specialty, and Optum specialty pharmacy have been the world's top five specialty pharmacies, based on the Drug Channels Institute's report 2021.

Start-ups offering Head and Neck Cancer Therapeutic Solutions

prominent start-up Players in the head and neck cancer (HNC) therapeutics market sector are introducing novel and innovative product lines to strengthen their market presence, and the aforementioned start-ups have left no stone unturned. The following are some specific examples of significant head and neck cancer (HNC) therapeutics market start-ups:

  • PDS Biotechnology Corporation, headquarters is located in North Brunswick, New Jersey, and was established in 2005. In May 2021, the Head and Neck Cancer Alliance (HNCA) and PDS Biotechnology Corporation entered into a partnership. This partnership aims to raise public awareness of emerging and new treatment choices for individuals diagnosed with HPV-related head and neck cancer, along with ongoing medical studies.
  • Incyte Corporation was established in 2002. Incyte Corporation (US) and AstraZeneca's global biologics study and development arm, MedImmune, have enlarged their medical collaboration. The companies agreed to contrast the effectiveness and safety of epacadostat, Incyte's investigational selective IDO1 enzyme inhibitor, with AstraZeneca's Imfinzi (durvalumab), a human monoclonal antibody oriented against PD-L1, to Imfinzi by itself.

Market Competition

Key players in the head and neck cancer (HNC) therapeutics markets are Eli Lilly and Company, Sanofi, Merck & Co., Inc., Clinigen Group plc., Bristol-Myers Squibb Company, AstraZeneca, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd, Hoffmann-La Roche Ltd., Coherus BioSciences.

  • Sanofi reimbursed US$ 1 billion to acquire Amunix Pharmaceuticals, Inc. in December 2021. This acquisition expands the corporation's oncology product portfolio and provides a significant opportunity for growth.
  • The US Food and Drug Administration (FDA) authorized KEYTRUDA, Merck's anti-PD-1 therapy, in conjunction with chemotherapy, including or without bevacizumab, in October 2021. Merck & Co., Inc.'s Keytruda is administered intravenously as an infusion in individuals who have head and neck cancer.

Report Scope

Report Attribute Details
Expected Market Value (2023) US$ 1.58 Billion
Anticipated Forecast Value (2033) US$ 5.19 Billion
Projected Growth Rate (2023 to 2033) 12.6% CAGR
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in US$ Billion and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
  • Therapy Type
  • Route of Administration
  • Channel
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa (MEA)
Key Countries Profiled
  • USA
  • Canada
  • Brazil
  • Mexico
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • India
  • Malaysia
  • Singapore
  • Thailand
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • GCC
  • South Africa
  • Israel
Key Companies Profiled Eli Lilly and Company, Sanofi, Merck & Co., Inc., Clinigen Group plc., Bristol-Myers Squibb Company, AstraZeneca, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd, Hoffmann-La Roche Ltd., Coherus BioSciences.
Customization Available Upon Request

Key Segments Profiled in the Head and Neck Cancer (HNC) Therapeutics Market Industry Survey 

By Therapy Type:

  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy

By Route of Administration:

  • Injectable
  • Oral
  • By Channel

Retail & Specialty Pharmacies:

  • Hospital Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa (MEA)

Frequently Asked Questions

What is the Projected Size of the Market by 2033?

The global market size to reach US$ 5.19 billion by 2033.

How Big is the Head and Neck Cancer (HNC) Therapeutics Market?

The market is valued at US$ 1.58 billion in 2023.

Who are the Key Head and Neck Cancer (HNC) Therapeutics Market Players?

Eli Lilly and Company, Sanofi, Merck & Co., Inc., and Clinigen Group plc. are the key market players.

What was North America's global share in 2021?

North America is likely to generate 45% revenue in 2021.

Which Therapy Type Hold Lucrative Opportunities?

Immunotherapy is estimated to hold lucrative opportunities in the forecast period.

Table of Content

1. Executive Summary | Head and Neck Cancer (HNC) Therapeutics Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Therapy Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapy Type, 2023 to 2033

        5.3.1. Chemotherapy

        5.3.2. Immunotherapy

        5.3.3. Targeted Therapy

    5.4. Y-o-Y Growth Trend Analysis By Therapy Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Therapy Type, 2023 to 2033

6. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033

        6.3.1. Injectable

        6.3.2. Oral

    6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033

7. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Channel

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Channel, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Channel, 2023 to 2033

        7.3.1. Retail & Specialty Pharmacies

        7.3.2. Hospital Pharmacies

        7.3.3. Online Pharmacies

    7.4. Y-o-Y Growth Trend Analysis By Channel, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Channel, 2023 to 2033

8. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. Asia Pacific

        8.3.5. Middle East & Africa (MEA)

    8.4. Market Attractiveness Analysis By Region

9. North America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. USA

            9.2.1.2. Canada

        9.2.2. By Therapy Type

        9.2.3. By Route of Administration

        9.2.4. By Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Therapy Type

        9.3.3. By Route of Administration

        9.3.4. By Channel

    9.4. Key Takeaways

10. Latin America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Therapy Type

        10.2.3. By Route of Administration

        10.2.4. By Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Therapy Type

        10.3.3. By Route of Administration

        10.3.4. By Channel

    10.4. Key Takeaways

11. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. UK

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Therapy Type

        11.2.3. By Route of Administration

        11.2.4. By Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Therapy Type

        11.3.3. By Route of Administration

        11.3.4. By Channel

    11.4. Key Takeaways

12. Asia Pacific Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

            12.2.1.4. Singapore

            12.2.1.5. Thailand

            12.2.1.6. Indonesia

            12.2.1.7. Australia

            12.2.1.8. New Zealand

            12.2.1.9. Rest of Asia Pacific

        12.2.2. By Therapy Type

        12.2.3. By Route of Administration

        12.2.4. By Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Therapy Type

        12.3.3. By Route of Administration

        12.3.4. By Channel

    12.4. Key Takeaways

13. MEA Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. GCC Countries

            13.2.1.2. South Africa

            13.2.1.3. Israel

            13.2.1.4. Rest of MEA

        13.2.2. By Therapy Type

        13.2.3. By Route of Administration

        13.2.4. By Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Therapy Type

        13.3.3. By Route of Administration

        13.3.4. By Channel

    13.4. Key Takeaways

14. Key Countries Analysis

    14.1. USA

        14.1.1. Pricing Analysis

        14.1.2. Market Share Analysis, 2022

            14.1.2.1. By Therapy Type

            14.1.2.2. By Route of Administration

            14.1.2.3. By Channel

    14.2. Canada

        14.2.1. Pricing Analysis

        14.2.2. Market Share Analysis, 2022

            14.2.2.1. By Therapy Type

            14.2.2.2. By Route of Administration

            14.2.2.3. By Channel

    14.3. Brazil

        14.3.1. Pricing Analysis

        14.3.2. Market Share Analysis, 2022

            14.3.2.1. By Therapy Type

            14.3.2.2. By Route of Administration

            14.3.2.3. By Channel

    14.4. Mexico

        14.4.1. Pricing Analysis

        14.4.2. Market Share Analysis, 2022

            14.4.2.1. By Therapy Type

            14.4.2.2. By Route of Administration

            14.4.2.3. By Channel

    14.5. Germany

        14.5.1. Pricing Analysis

        14.5.2. Market Share Analysis, 2022

            14.5.2.1. By Therapy Type

            14.5.2.2. By Route of Administration

            14.5.2.3. By Channel

    14.6. UK

        14.6.1. Pricing Analysis

        14.6.2. Market Share Analysis, 2022

            14.6.2.1. By Therapy Type

            14.6.2.2. By Route of Administration

            14.6.2.3. By Channel

    14.7. France

        14.7.1. Pricing Analysis

        14.7.2. Market Share Analysis, 2022

            14.7.2.1. By Therapy Type

            14.7.2.2. By Route of Administration

            14.7.2.3. By Channel

    14.8. Spain

        14.8.1. Pricing Analysis

        14.8.2. Market Share Analysis, 2022

            14.8.2.1. By Therapy Type

            14.8.2.2. By Route of Administration

            14.8.2.3. By Channel

    14.9. Italy

        14.9.1. Pricing Analysis

        14.9.2. Market Share Analysis, 2022

            14.9.2.1. By Therapy Type

            14.9.2.2. By Route of Administration

            14.9.2.3. By Channel

    14.10. China

        14.10.1. Pricing Analysis

        14.10.2. Market Share Analysis, 2022

            14.10.2.1. By Therapy Type

            14.10.2.2. By Route of Administration

            14.10.2.3. By Channel

    14.11. Japan

        14.11.1. Pricing Analysis

        14.11.2. Market Share Analysis, 2022

            14.11.2.1. By Therapy Type

            14.11.2.2. By Route of Administration

            14.11.2.3. By Channel

    14.12. South Korea

        14.12.1. Pricing Analysis

        14.12.2. Market Share Analysis, 2022

            14.12.2.1. By Therapy Type

            14.12.2.2. By Route of Administration

            14.12.2.3. By Channel

    14.13. Singapore

        14.13.1. Pricing Analysis

        14.13.2. Market Share Analysis, 2022

            14.13.2.1. By Therapy Type

            14.13.2.2. By Route of Administration

            14.13.2.3. By Channel

    14.14. Thailand

        14.14.1. Pricing Analysis

        14.14.2. Market Share Analysis, 2022

            14.14.2.1. By Therapy Type

            14.14.2.2. By Route of Administration

            14.14.2.3. By Channel

    14.15. Indonesia

        14.15.1. Pricing Analysis

        14.15.2. Market Share Analysis, 2022

            14.15.2.1. By Therapy Type

            14.15.2.2. By Route of Administration

            14.15.2.3. By Channel

    14.16. Australia

        14.16.1. Pricing Analysis

        14.16.2. Market Share Analysis, 2022

            14.16.2.1. By Therapy Type

            14.16.2.2. By Route of Administration

            14.16.2.3. By Channel

    14.17. New Zealand

        14.17.1. Pricing Analysis

        14.17.2. Market Share Analysis, 2022

            14.17.2.1. By Therapy Type

            14.17.2.2. By Route of Administration

            14.17.2.3. By Channel

    14.18. GCC Countries

        14.18.1. Pricing Analysis

        14.18.2. Market Share Analysis, 2022

            14.18.2.1. By Therapy Type

            14.18.2.2. By Route of Administration

            14.18.2.3. By Channel

    14.19. South Africa

        14.19.1. Pricing Analysis

        14.19.2. Market Share Analysis, 2022

            14.19.2.1. By Therapy Type

            14.19.2.2. By Route of Administration

            14.19.2.3. By Channel

    14.20. Israel

        14.20.1. Pricing Analysis

        14.20.2. Market Share Analysis, 2022

            14.20.2.1. By Therapy Type

            14.20.2.2. By Route of Administration

            14.20.2.3. By Channel

15. Market Structure Analysis

    15.1. Competition Dashboard

    15.2. Competition Benchmarking

    15.3. Market Share Analysis of Top Players

        15.3.1. By Regional

        15.3.2. By Therapy Type

        15.3.3. By Route of Administration

        15.3.4. By Channel

16. Competition Analysis

    16.1. Competition Deep Dive

        16.1.1. Eli Lilly and Company

            16.1.1.1. Overview

            16.1.1.2. Product Portfolio

            16.1.1.3. Profitability by Market Segments

            16.1.1.4. Sales Footprint

            16.1.1.5. Strategy Overview

                16.1.1.5.1. Marketing Strategy

        16.1.2. Sanofi

            16.1.2.1. Overview

            16.1.2.2. Product Portfolio

            16.1.2.3. Profitability by Market Segments

            16.1.2.4. Sales Footprint

            16.1.2.5. Strategy Overview

                16.1.2.5.1. Marketing Strategy

        16.1.3. Merck & Co., Inc.

            16.1.3.1. Overview

            16.1.3.2. Product Portfolio

            16.1.3.3. Profitability by Market Segments

            16.1.3.4. Sales Footprint

            16.1.3.5. Strategy Overview

                16.1.3.5.1. Marketing Strategy

        16.1.4. Clinigen Group plc.

            16.1.4.1. Overview

            16.1.4.2. Product Portfolio

            16.1.4.3. Profitability by Market Segments

            16.1.4.4. Sales Footprint

            16.1.4.5. Strategy Overview

                16.1.4.5.1. Marketing Strategy

        16.1.5. Bristol-Myers Squibb Company

            16.1.5.1. Overview

            16.1.5.2. Product Portfolio

            16.1.5.3. Profitability by Market Segments

            16.1.5.4. Sales Footprint

            16.1.5.5. Strategy Overview

                16.1.5.5.1. Marketing Strategy

        16.1.6. AstraZeneca

            16.1.6.1. Overview

            16.1.6.2. Product Portfolio

            16.1.6.3. Profitability by Market Segments

            16.1.6.4. Sales Footprint

            16.1.6.5. Strategy Overview

                16.1.6.5.1. Marketing Strategy

        16.1.7. Takeda Pharmaceutical Company Limited

            16.1.7.1. Overview

            16.1.7.2. Product Portfolio

            16.1.7.3. Profitability by Market Segments

            16.1.7.4. Sales Footprint

            16.1.7.5. Strategy Overview

                16.1.7.5.1. Marketing Strategy

        16.1.8. Teva Pharmaceutical Industries Ltd

            16.1.8.1. Overview

            16.1.8.2. Product Portfolio

            16.1.8.3. Profitability by Market Segments

            16.1.8.4. Sales Footprint

            16.1.8.5. Strategy Overview

                16.1.8.5.1. Marketing Strategy

        16.1.9. F. Hoffmann-La Roche Ltd.

            16.1.9.1. Overview

            16.1.9.2. Product Portfolio

            16.1.9.3. Profitability by Market Segments

            16.1.9.4. Sales Footprint

            16.1.9.5. Strategy Overview

                16.1.9.5.1. Marketing Strategy

        16.1.10. Coherus BioSciences

            16.1.10.1. Overview

            16.1.10.2. Product Portfolio

            16.1.10.3. Profitability by Market Segments

            16.1.10.4. Sales Footprint

            16.1.10.5. Strategy Overview

                16.1.10.5.1. Marketing Strategy

17. Assumptions & Acronyms Used

18. Research Methodology

Recommendations

Healthcare

Cancer Diagnostics Market

Published : August 2023

Healthcare

PD1 Resistant Head and Neck Cancer Market

Published : December 2022

Explore Healthcare Insights

View Reports

Head and Neck Cancer (HNC) Therapeutics Market